Preventing portal hypertension necessitates addressing the underlying cause of liver disease, such as weight reduction and avoidance of excessive alcohol use.
Hepatitis B vaccination, and the wider availability of direct antiviral agents for hepatitis C and chronic hepatitis B, will reduce disease burden and subsequent cirrhosis.[25]Young K, Liu B, Bhuket T, et al. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States. J Viral Hepat. 2019 Mar;26(3):350-61.
http://www.ncbi.nlm.nih.gov/pubmed/30412318?tool=bestpractice.com
[28]Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-99.
https://www.doi.org/10.1002/hep.29800
http://www.ncbi.nlm.nih.gov/pubmed/29405329?tool=bestpractice.com
Patients with acute variceal hemorrhage are at high risk of rebleeding.
Once stabilized, patients should be treated with nonselective beta-blockers to reduce variceal rebleeding unless shunt therapy has been performed. Clinical and hemodynamic studies indicate that carvedilol (which is both a nonselective beta-blocker and an alpha-1 adrenergic receptor blocker) may be an effective alternative to nonselective beta-blockers.[69]Tripathi D, Hayes PC. The role of carvedilol in the management of portal hypertension. Eur J Gastroenterol Hepatol. 2010 Aug;22(8):905-11.
http://www.ncbi.nlm.nih.gov/pubmed/20093937?tool=bestpractice.com
Repeat endoscopic therapy should be performed every 2-3 weeks until varices are completely eradicated. Endoscopic surveillance schedule after variceal eradication by banding ligation is 3 months, then after 6 months, and then yearly.[37]de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022 Apr;76(4):959-74.
https://www.journal-of-hepatology.eu/article/S0168-8278(21)02299-6/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/35120736?tool=bestpractice.com
Combination medical therapy and endoscopic ligation is currently considered the best option to prevent rebleeding.[5]Kaplan DE, Ripoll C, Thiele M, et al. AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024 May 1;79(5):1180-211.
https://journals.lww.com/hep/fulltext/2024/05000/aasld_practice_guidance_on_risk_stratification_and.22.aspx
http://www.ncbi.nlm.nih.gov/pubmed/37870298?tool=bestpractice.com
[37]de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022 Apr;76(4):959-74.
https://www.journal-of-hepatology.eu/article/S0168-8278(21)02299-6/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/35120736?tool=bestpractice.com
[38]Tripathi D, Stanley AJ, Hayes PC, et al. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015 Nov;64(11):1680-704.
https://gut.bmj.com/content/64/11/1680.long
http://www.ncbi.nlm.nih.gov/pubmed/25887380?tool=bestpractice.com
In patients who have episodes of rebleeding despite combination therapy, a transjugular intrahepatic porto-systemic shunt (TIPS) should be considered.[5]Kaplan DE, Ripoll C, Thiele M, et al. AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024 May 1;79(5):1180-211.
https://journals.lww.com/hep/fulltext/2024/05000/aasld_practice_guidance_on_risk_stratification_and.22.aspx
http://www.ncbi.nlm.nih.gov/pubmed/37870298?tool=bestpractice.com
[38]Tripathi D, Stanley AJ, Hayes PC, et al. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015 Nov;64(11):1680-704.
https://gut.bmj.com/content/64/11/1680.long
http://www.ncbi.nlm.nih.gov/pubmed/25887380?tool=bestpractice.com
[56]Lee EW, Eghtesad B, Garcia-Tsao G, et al. AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage. Hepatology. 2024 Jan 1;79(1):224-50.
https://journals.lww.com/hep/fulltext/2024/01000/aasld_practice_guidance_on_the_use_of_tips,.23.aspx
http://www.ncbi.nlm.nih.gov/pubmed/37390489?tool=bestpractice.com
A distal splenorenal surgical shunt is an alternative to TIPS in patients with nonemergent bleeding who have compensated liver disease.[70]Henderson JM, Boyer TD, Kutner MH, et al. Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial. Gastroenterology. 2006 May;130(6):1643-51.
http://www.ncbi.nlm.nih.gov/pubmed/16697728?tool=bestpractice.com
[
]
For adults with cirrhosis and variceal hemorrhage, how do surgical and transjugular intrahepatic portosystemic shunts compare?/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.2389/fullShow me the answer